intravitreal ranibizumab & photodynamic therapy — Competitive Intelligence Brief

intravitreal ranibizumab & photodynamic therapy (intravitreal ranibizumab & photodynamic therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-VEGF agent. Area: Ophthalmology.

phase 3 Anti-VEGF agent VEGF-A Ophthalmology Small molecule

Target snapshot

intravitreal ranibizumab & photodynamic therapy (intravitreal ranibizumab & photodynamic therapy) — University Hospital, Basel, Switzerland. Intravitreal ranibizumab inhibits vascular endothelial growth factor A (VEGF-A) by binding to its receptor, reducing angiogenesis and edema in the retina.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
intravitreal ranibizumab & photodynamic therapy TARGET	intravitreal ranibizumab & photodynamic therapy	University Hospital, Basel, Switzerland	phase 3	Anti-VEGF agent	VEGF-A
Aflibercept (Eylea)	Aflibercept (Eylea)	Ahmad Zeeshan Jamil	marketed	VEGF inhibitor / Soluble decoy receptor	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)
intra-vitreal injection of Ranibizumab	intra-vitreal injection of Ranibizumab	Ain Shams University	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
aflibercept + FOLFIRI	aflibercept + FOLFIRI	CR-CSSS Champlain-Charles-Le Moyne	marketed	VEGF inhibitor (fusion protein) + chemotherapy combination	VEGF-A, VEGF-B, PlGF (aflibercept component); topoisomerase I and thymidylate synthase (FOLFIRI component)
Lucentis (Treat and extend)	Lucentis (Treat and extend)	Retinal Consultants of Arizona	marketed	VEGF inhibitor (monoclonal antibody fragment)	VEGF-A
Aflibercept and ranibizumab	Aflibercept and ranibizumab	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (and VEGF-B for aflibercept)
Aflibercept Injection [Eylea]	Aflibercept Injection [Eylea]	Caregen Co. Ltd.	marketed	VEGF inhibitor (soluble decoy receptor)	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-VEGF agent class)

1. Instituto de Olhos de Goiania · 2 drugs in this class
2. University Hospital, Basel, Switzerland · 1 drug in this class